Larimar Therapeutics' Cash, Cash Equivalents, And Marketable Securities Of $239M As Of March 31, 2024, Extends Projected Cash Runway Into 2026
Larimar Therapeutics' Cash, Cash Equivalents, And Marketable Securities Of $239M As Of March 31, 2024, Extends Projected Cash Runway Into 2026
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.